https://orcid.org/0000-0002-3839-6966
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Grant McCarthy, Kate Young, Matthew Madin-Warburton, Tyler Mantaian, Elizabeth Brook, Kaylie Metcalfe, Jan Mikelson, Ruifeng Xu, Carl Seyla-Hammer, Raquel Aguiar-Ibáñez & Mayur Amonkar. (2024) Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK. Journal of Medical Economics 27:1, pages 279-291.
Read now
Read now
Ivo Abraham, Kenneth K. C. Lee & Mike Gregg. (2023) Journal of Medical Economics in review: high impact articles from 2022. Journal of Medical Economics 26:1, pages 303-307.
Read now
Read now
Tong Liu, Shuang Liu, Shangwei Guan, Yu Tai, Yao Jin & Mei Dong. (2023) Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. Journal of Chemotherapy 35:8, pages 745-752.
Read now
Read now
Gaayathri Kumarasamy, Nurul Hakimah Mohd Salim, Nur Syafiqah Mohd Afandi, Mohd Afiq Hazlami Habib, Nor Datiakma Mat Amin, Mohd Nazri Ismail & Marahaini Musa. (2023) Glycoproteomics-Based Liquid Biopsy: Translational Outlook for Colorectal Cancer Clinical Management in Southeast Asia. Future Oncology 19:34, pages 2313-2332.
Read now
Read now
Blair McNamara, Yifan Chang, Levent Mutlu, Justin Harold & Alessandro D Santin. (2023) Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion on Biological Therapy 23:3, pages 227-233.
Read now
Read now
Articles from other publishers (5)
Kiyoaki Sugiura, Hiroki Hiratsuka, Go Oshima & Satoshi Aiko. (2023) Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan. Japanese Journal of Clinical Oncology 53:8, pages 691-697.
Crossref
Crossref
Yue Ma, Jiting Zhou, Yuxin Ye, Xintian Wang, Aixia Ma & Hongchao Li. (2023) The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China. Frontiers in Oncology 13.
Crossref
Crossref
Muhammad Usman Ashraf, Ume Farwa, Maryam Siddiqa, Azza Sarfraz, Nishwa Azeem & Zouina Sarfraz. (2023) Has the Landscape of Immunotherapy for Prostate Cancer Changed? A Systematic Review and Post Hoc Analysis. American Journal of Men's Health 17:2, pages 155798832311651.
Crossref
Crossref
Chad Moretz, Stacey DaCosta Byfield, Kathryn E. Hatchell, Joline Dalton, Peter Nicholas Onglao, Lillian Hang, Pamela Hansen, Cristi Radford, Sarah M. Nielsen, Brandie Heald, Sandra B. Munro, Robert L. Nussbaum & Edward D. Esplin. (2022) Comparison of Germline Genetic Testing Before and After a Medical Policy Covering Universal Testing Among Patients With Colorectal Cancer. JAMA Network Open 5:10, pages e2238167.
Crossref
Crossref
Zhiwei Zheng, Jingrong Lin, Huide Zhu & Hongfu Cai. (2022) Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More. Frontiers in Public Health 10.
Crossref
Crossref